Evidence map›Paper›PMID 41256840›Full record

ArticleFrontiers in immunology2025

An mRNA-based FimH nanoparticle vaccine against uropathogenic

Sandro Roier, Roberto Adamo, Roberto Rosini, Alfredo Pezzicoli, Maria Scarselli, Benjamin Petsch, Edith Jasny, Susanne Rauch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. UropathogenicAntibiotics (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Protein-centric mechanisms of typhoidalFrontiers in cellular and infection microbiology · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sandro RoierCureVac SE, Tübingen, Germany.
Roberto AdamoGSK, Siena, Italy.
Roberto RosiniGSK, Siena, Italy.
Alfredo PezzicoliGSK, Siena, Italy.
Maria ScarselliGSK, Siena, Italy.
Benjamin PetschCureVac SE, Tübingen, Germany.
Edith JasnyCureVac SE, Tübingen, Germany.
Susanne RauchCureVac SE, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Uropathogenic Methods: Lipid nanoparticle (LNP)-formulated mRNA vaccines encoding FimH as a monomeric, pre-binding conformation protein (FimH Results: In both animal models, unmodified FimH Conclusions: The mRNA vaccine FimH

Indexed as

Adhesins, Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesFimbriae ProteinsImmunogenicity, VaccineNanoparticlesRNA, MessengerUrinary Tract InfectionsUropathogenic Escherichia coliAnimalsAntibodies, BacterialFemaleFerritinsMiceMice, Inbred BALB CNanovaccinesAdhesins, Escherichia coliAntibodies, BacterialEscherichia coli VaccinesFerritinsFimbriae ProteinsfimH protein, E coliNanovaccinesRNA, MessengerFimHmRNA vaccinenanoparticleUPECUPEC vaccineurinary tract infectionuropathogenic E. coli

Identifiers

PMID41256840
PMCPMC12620438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.